Reviews Open access

An overview of the relation between tuberculosis and autoantibodies: a systematic review

Authors

Published
9 September 2026
Section
Reviews
DOI
10.4081/reumatismo.2026.1905

Abstract

Objective. Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a significant global health concern. While traditionally viewed as an infectious disease primarily affecting the lungs, accumulating evidence suggests a complex interplay between TB and the host’s immune system, potentially leading to the production of autoantibodies. This systematic review aims to investigate the frequency of autoantibody positivity among active TB patients.

Methods. A comprehensive search of major electronic databases such as PubMed, Scopus, Google Scholar, and Web of Science was performed. The search strategy employed keywords including “tuberculosis”, “autoantibodies”, and specific autoantibody names such as “ANA”, “Anti-dsDNA”, “Anti-phospholipid”, “ANCA”, “RF” and “ACPA” to study the link between TB and autoantibodies. How often autoantibodies are found in TB patients and what this means for diagnosis and treatment, was analyzed.

Results. The results indicate a diverse spectrum of autoantibodies among patients with TB. Some of the autoantibodies, such as rheumatoid factor and anti-phospholipid antibodies, are frequently detected. This can pose diagnostic challenges by mimicking autoimmune diseases and may have implications for monitoring treatment response. Furthermore, the bidirectional relationship between TB and autoimmune diseases, where one can increase the risk of the other, underscores the need for careful clinical consideration.

Conclusions. Understanding this complex association is crucial for improving the management of TB, especially in individuals with or at risk of autoimmune conditions.

Keywords

References

  1. Bagcchi S. WHO's global tuberculosis report 2022. Lancet Microbe 2023; 4: e20. DOI: https://doi.org/10.1016/S2666-5247(22)00359-7
  2. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol 2023; 19: 509-24. DOI: https://doi.org/10.1038/s41581-023-00720-1
  3. Nielsen PR, Kragstrup TW, Deleuran BW, Benros ME. Infections as risk factor for autoimmune diseases–a nationwide study. Journal of autoimmunity 2016; 74: 176-81. DOI: https://doi.org/10.1016/j.jaut.2016.05.013
  4. Belyaeva IV, Kosova AN, Vasiliev AG. Tuberculosis and autoimmunity. Pathophysiology 2022; 29: 298-318. DOI: https://doi.org/10.3390/pathophysiology29020022
  5. Yablonskiy PK, Belyaeva IV, Churilov LP, Erman MV, Kudryavtsev IV, Malkova АM, et al. Tuberculosis and autoimmunity: well-coordinated duo. In: Infection and autoimmunity. Cambridge, MA, USA: Academic Press; 2024. pp. 517-41. DOI: https://doi.org/10.1016/B978-0-323-99130-8.00018-0
  6. Galipeau Y, Cooper C, Langlois MA. Autoantibodies in COVID-19: implications for disease severity and clinical outcomes. Front Immunol 2025; 15: 1509289. DOI: https://doi.org/10.3389/fimmu.2024.1509289
  7. Dobrowolska K, Zarębska‐Michaluk D, Poniedziałek B, Jaroszewicz J, Flisiak R, Rzymski P. Overview of autoantibodies in COVID‐19 convalescents. J Med Virol 2023; 95: e28864. DOI: https://doi.org/10.1002/jmv.28864
  8. Tugwell P, Tovey D. PRISMA 2020. J Clin Epidemiol 2021; 134: A5-6. DOI: https://doi.org/10.1016/j.jclinepi.2021.04.008
  9. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa 2014: B-10.
  10. Cheng MP, Butler-Laporte G, Parkes LO, Bold TD, Fritzler MJ, Behr MA. Prevalence of auto-antibodies in pulmonary tuberculosis. Open Forum Infect Dis 2019; 6: ofz114. DOI: https://doi.org/10.1093/ofid/ofz114
  11. Elkayam O, Caspi D, Lidgi M, Segal R. Auto-antibody profiles in patients with active pulmonary tuberculosis. Int J Tuberc Lung Dis 2007; 11: 306-10.
  12. Faris MH, Athab AM, Fadhil RM. Evaluation of auto-antibody profiles in patients with tuberculosis. DJM 2018; 15: 50-60. DOI: https://doi.org/10.26505/DJM.15014050429
  13. Emami S. Serum level of anti-CCP in patients with active pulmonary tuberculosis. Biomed J Sci Tech Res 2017; 1: 947-50. DOI: https://doi.org/10.26717/BJSTR.2017.01.000338
  14. Naher N, Imam H, Biswas SK, Biswas T, Azad M, Hasan MN, et al. Frequency of positive antinuclear antibody in people with active tuberculosis and its changes with antitubercular therapy. Cureus 2025; 17: e81116. DOI: https://doi.org/10.7759/cureus.81116
  15. Chander Y, Acharya N, Naidu GS, Rathi M, Minz R, Jain S, et al. Prevalence of antineutrophil cytoplasmic antibodies and antinuclear antibodies in patients with pulmonary tuberculosis: a tertiary care center experience from north India. J Assoc Physicians India 2022; 70: 11-2. DOI: https://doi.org/10.5005/japi-11001-0126
  16. Pradhan VD, Badakere SS, Ghosh K, Pawar AR. Spectrum of anti-neutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis overlaps with that of Wegener’s granulomatosis. Indian J Med Sci 2004; 58: 283-8.
  17. Adebajo AO, Charles P, Maini RN, Hazleman BL. Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population. Clin Exp Immunol 1993; 92: 73-6. DOI: https://doi.org/10.1111/j.1365-2249.1993.tb05950.x
  18. Isenberg DA, Maddison P, Swana G, Skinner RP, Swana M, Jones M, et al. Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections. Clin Exp Immunol 1987; 67: 516-23.
  19. Shen CY, Hsieh SC, Yu CL, Wang JY, Lee LN, Yu CJ. Autoantibody prevalence in active tuberculosis: reactive or pathognomonic? BMJ Open 2013; 3: e002665. DOI: https://doi.org/10.1136/bmjopen-2013-002665
  20. Shahzad F, Ali A, Mushtaq A, Javaid K, Nazir A, Pervez A, et al. Raised dsDNA autoantibodies in tuberculosis patients. Egypt J Chest Dis Tuberc 2019; 68: 28-31. DOI: https://doi.org/10.4103/ejcdt.ejcdt_98_18
  21. Ms G, Narasimhan PB, Kavadichanda C, Gopal A, Bairwa D, Thabah MM, et al. AB0558 prevalence of latent tuberculosis infection and its associations with clinical and serological parameters in systemic lupus erythematosus. Ann Rheum Dis 2022; 81: 1406. DOI: https://doi.org/10.1136/annrheumdis-2022-eular.4680
  22. Elkayam O, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 2006; 65: 1110-2. DOI: https://doi.org/10.1136/ard.2005.045229
  23. Starshinova A, Malkova A, Zinchenko Y, Kudryavtsev I, Serebriakova M, Akisheva T, et al. Identification of autoimmune markers in pulmonary tuberculosis. Front Immunol 2023; 13: 1059714. DOI: https://doi.org/10.3389/fimmu.2022.1059714
  24. Lima I, Oliveira RC, Atta A, Marchi S, Barbosa L, Reis E, et al. Antibodies to citrullinated peptides in tuberculosis. Clin Rheumatol 2013;32:685-7. DOI: https://doi.org/10.1007/s10067-013-2173-y
  25. Rapoport BL, Morrison RC, Sher R, Dos Santos L. A study of autoantibodies in chronic mycobacterial infections. Int J Lepr Other Mycobact Dis 1990; 58: 518-25.
  26. Elkayam O, Segal R, Bendayan D, van Uitert R, Onnekink C, Pruijn GJ. The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment. Arthritis Res Ther 2010; 12: R12. DOI: https://doi.org/10.1186/ar2913
  27. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti–cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine‐containing peptide. Arthritis Rheum 2008; 58: 1576-81. DOI: https://doi.org/10.1002/art.23514
  28. Elkayam O, Bendayan D, Segal R, Shapira Y, Gilburd B, Reuter S, et al. The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. Rheumatol Int 2013; 33: 949-53. DOI: https://doi.org/10.1007/s00296-012-2487-0
  29. Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Tuberculosis 2012; 92: 243-7. DOI: https://doi.org/10.1016/j.tube.2012.02.004
  30. Takenami I, De Oliveira CC, Petrilli JD, Machado A, Riley LW, Arruda S. Serum antiphospholipid antibody levels as biomarkers for diagnosis of pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2018; 22: 1063-70. DOI: https://doi.org/10.5588/ijtld.17.0874
  31. Bessis S, Bertin D, Million M, Meddeb L, Drancourt M, Lagier JC, et al. Thromboses in tuberculosis are linked to antiphosphatidylethanolamine antibodies levels: a cross-sectional study. J Clin Tuberc Other Mycobact Dis 2019; 15: 100092. DOI: https://doi.org/10.1016/j.jctube.2019.100092
  32. Sherkat R, Mostafavizadeh K, Zeydabadi L, Shoaei P, Rostami S. Antineutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis. Iran J Immunol 2011; 8: 52-7.
  33. Hussein S, Ismael M, Abdulmajeed N. Antineutrophil cytoplasmic antibodies in patients with tuberculosis. Iraqi J Sci 2014; 55: 360-6.
  34. Teixeira L, Mahr A, Jaureguy F, Noel LH, Nunes H, Lefort A, et al. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology 2005; 44: 247-50. DOI: https://doi.org/10.1093/rheumatology/keh467
  35. Esquivel-Valerio JA, Flores-Suárez LF, Rodríguez-Amado J, Garza-Elizondo MA, Rendón A, Salinas-Carmona MC. Antineutrophil cytoplasm autoantibodies in patients with tuberculosis are directed against bactericidal/permeability increasing protein and are detected after treatment initiation. Clin Exp Rheumatol 2010; 28: 35-9.
  36. Flores‐Suárez LF, Cabiedes J, Villa AR, Van der Woude FJ, Alcocer‐Varela J. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology 2003; 42: 223-9. DOI: https://doi.org/10.1093/rheumatology/keg066
  37. Lima I, Oliveira RC, Cabral MS, Atta A, Marchi S, Reis E, et al. Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis. Rheumatol Int 2014; 34: 1231-4. DOI: https://doi.org/10.1007/s00296-014-3009-z
  38. Huan G, Yang G, Xiao-Yu Q, Jiancheng X, Yan-Qing S. Antineutrophil cytoplasmic antibodies in Chinese patients with tuberculosis. Rev Soc Bras Med Trop 2018; 51: 475-8. DOI: https://doi.org/10.1590/0037-8682-0400-2017
  39. Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. J Microbiol Immunol Infect 2014; 47: 268-74. DOI: https://doi.org/10.1016/j.jmii.2013.03.005
  40. Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Lagana B, Gatta L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 2014; 46: 547-54 DOI: https://doi.org/10.3109/07853890.2014.941919
  41. Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori GB, Goletti D. Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents. Front Immunol 2025; 16: 1494283. DOI: https://doi.org/10.3389/fimmu.2025.1494283
  42. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-52. DOI: https://doi.org/10.1016/j.autrev.2008.07.011
  43. Wu Q, Liu Y, Wang W, Zhang Y, Liu K, Chen SH, Chen B. Incidence and prevalence of tuberculosis in systemic lupus erythematosus patients: a systematic review and meta-analysis. Front Immunol 2022; 13: 938406. DOI: https://doi.org/10.3389/fimmu.2022.938406
  44. Chang YS, Liu CJ, Ou SM, Hu YW, Chen TJ, Lee HT, et al. Tuberculosis infection in primary Sjögren’s syndrome: a nationwide population-based study. Clin Rheumatol 2014; 33: 377-83. DOI: https://doi.org/10.1007/s10067-013-2408-y
  45. Starshinova A, Malkova А, Kudryavtsev I, Kudlay D, Zinchenko Y, Yablonskiy P. Tuberculosis and autoimmunity: common features. Tuberculosis 2022; 134: 102202. DOI: https://doi.org/10.1016/j.tube.2022.102202
  46. Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: tuberculosis and splenectomy as possible triggering factors? Another example of the “mosaic” of autoimmunity. J Rheumatol 2008; 35: 1224-6.
  47. Rueda JC, Crepy MF, Mantilla RD. Clinical features of Poncet’s disease. From the description of 198 cases found in the literature. Clin Rheumatol 2013; 32: 929-35. DOI: https://doi.org/10.1007/s10067-013-2270-y
  48. Liu Y, Che G, Liu Y, Xu K. Tuberculosis mimicking the onset of systemic lupus erythematosus flare: case based review. Int J Rheum Dis 2023; 26: 1143-8. DOI: https://doi.org/10.1111/1756-185X.14585
  49. Lin YC, Liang SJ, Liu YH, Hsu WH, Shih CM, Sung FC, Chen W. Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan. Rheumatol Int 2012; 32: 1669-73. DOI: https://doi.org/10.1007/s00296-011-1847-5
  50. Shapira Y, Agmon-Levin N, Shoenfeld Y. Mycobacterium tuberculosis, autoimmunity, and vitamin D. Clin Rev Allergy Immunol 2010; 38: 169-77. DOI: https://doi.org/10.1007/s12016-009-8150-1

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.